Castle Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
of $344.2M (above guidance) and provided 2026 revenue guidance of $340–350M (mid-to-high teens growth ex DecisionDx-SCC/IDgenetix), while FY2025 net loss was $24.2M and cash and equivalents stood at about $299.5M. Volume growth driven by TissueCypher: Core test report volume rose 37% to 105,053 in 2025, led by TissueCypher (86% growth to 39,014 reports) and with DecisionDx-Melanoma up 9% to 39,083 reports (patient penetration exiting 2025 ~11% and ~31%, respectively). New launches and pipeline milestones: The company launched AdvanceAD-Tx in limited access (˜500 orders by mid-Feb 2026) but expects immaterial 2026 revenue, and is pursuing Previse and SciBase studies with Q2 2026 enrollments and preliminary data by year-end, plus a planned de novo 510(k) submission for DecisionDx-Melanoma targeting late 2026/early 2027. Interested in Castle Biosciences, Inc.? Here are five stocks we like better. Castle Biosciences (NASDAQ:CSTL) reported fourth-quarter revenue of $87.0 million an
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNBGlobeNewswire
- Castle Biosciences (CSTL) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
- Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, TexasGlobeNewswire
CSTL
Earnings
- 2/26/26 - Beat
CSTL
Sec Filings
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- CSTL's page on the SEC website